Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.
about
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Patient-specific molecular alt ...... sine kinase inhibitor therapy.
@en
Patient-specific molecular alt ...... sine kinase inhibitor therapy.
@nl
type
label
Patient-specific molecular alt ...... sine kinase inhibitor therapy.
@en
Patient-specific molecular alt ...... sine kinase inhibitor therapy.
@nl
prefLabel
Patient-specific molecular alt ...... sine kinase inhibitor therapy.
@en
Patient-specific molecular alt ...... sine kinase inhibitor therapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Patient-specific molecular alt ...... osine kinase inhibitor therapy
@en
P2093
Albrecht Stenzinger
Anja Lisa Riediger
Dirk Jäger
Eva Reisinger
Markus Hohenfellner
Sascha Pahernik
Stefan Duensing
Steffen Dietz
P2860
P304
74049-74057
P356
10.18632/ONCOTARGET.18200
P407
P577
2017-05-23T00:00:00Z